SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-053357
Filing Date
2023-11-15
Accepted
2023-11-15 09:00:32
Documents
12
Period of Report
2023-11-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20014753_8k.htm   iXBRL 8-K 31037
  Complete submission text file 0001140361-23-053357.txt   172398

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA knte-20231113.xsd EX-101.SCH 3862
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE knte-20231113_lab.xml EX-101.LAB 23290
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knte-20231113_pre.xml EX-101.PRE 16550
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20014753_8k_htm.xml XML 4425
Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Filer) CIK: 0001797768 (see all company filings)

IRS No.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39743 | Film No.: 231409180
SIC: 2834 Pharmaceutical Preparations